Skip to content
Sermorelin Picks
← Research
Evidence

Sermorelin's Marketing Claims, Ranked by Evidence

Anti-aging, sleep, recovery, body composition, libido and skin — sermorelin marketing makes all six claims. Here's what has actually been measured in humans for each one, and how weak the base is.

Adrian Osei6 min read
Six claims, one 1997 trial, ranked by what it found1. LibidoP < 0.01, men only2. Skin thicknessP < 0.05, both sexes3. Body compositionP < 0.05, men only4. Anti-aging / well-beingP < 0.05, men only5. Sleeptested — no change6. Recoverynever testedBar length is a reading aid, not a statistic. One trial, nineteen adults, never repeated.

Sermorelin marketing reaches for six benefits, roughly in this order of how often they show up on a seller’s page: anti-aging, better sleep, faster recovery, leaner body composition, higher libido, firmer skin. All six trace back to the same mechanism — sermorelin prompts the pituitary to release more of a person’s own growth hormone. What differs enormously is how much of that chain was ever tested in a human being, on an outcome anyone would notice. See what the underlying trial measured for the full outcome list this ranking draws from.

Almost the entire adult evidence base for these six claims is one trial: nineteen adults, ages 55 to 71, single-blind, placebo-controlled, five months, published in 1997 [1]. It has never been repeated. Ranking the claims below by evidence means ranking them by what that one study did or did not find. A live PubMed search for each claim on its own fills in the rest.

1. Libido: the strongest single number, from one trial

Libido carries the tightest p-value of the six claims ranked here. Men in the 1997 trial reported a significant improvement in libido (P < 0.01) — the tightest result of any endpoint measured [1]. Women reported no change. A PubMed search for sermorelin and libido returns exactly one record: this same trial. One small study, one sex, one number, never checked again in twenty-nine years.

2. Skin thickness: positive, and the least-marketed of the six

Skin thickness increased significantly (P < 0.05) in both men and women in the same trial [1] — a positive result in both sexes, unlike any other claim ranked here. A search for sermorelin paired with skin, wrinkle or collagen returns six records total. Five are unrelated pediatric or chemistry papers; the 1997 trial is the only human outcome study among them. It is a real, if narrow, finding: skin thickness, not fewer wrinkles or visible aging, and it has not been replicated either.

3. Body composition: real, but only in men

Lean body mass rose significantly (P < 0.05) in men in the 1997 trial, with no change in women [1]. Bone mineral density and every other body-composition measure were unchanged in either sex. A search for sermorelin alongside body composition, lean body mass or strength returns six records; only this one is a human outcome trial. This is the finding most often stretched into a general “body composition” claim, when the actual result covers one measure, in men only. See the sex-split before-and-after read of that same result.

4. Anti-aging and general well-being: one subjective measure, men only

“Anti-aging” is not a measured outcome; it is a bundle of the claims above plus self-reported well-being. The 1997 trial did test general well-being directly, using a quality-of-life questionnaire. It found a significant improvement (P < 0.05) in men, with no change in women [1]. That is the entire anti-aging evidence base: one subjective self-report measure, in one sex, from one unreplicated trial. The rest of “anti-aging” is the skin and body-composition findings above, repackaged under a broader word.

5. Sleep: tested directly, and it failed

Sleep is among the most heavily advertised sermorelin benefits, and it is also the claim with the cleanest negative result. The 1997 trial measured sleep quality directly. It reported no change in either sex [1]. A search for sermorelin and sleep returns eight records; none of them is a positive human sleep-outcome trial. This claim was tested, not ignored, and it did not hold up.

6. Recovery: never tested in a human trial

Recovery — from workouts, injury or surgery — sits at the bottom because no trial has tested it at all. A PubMed search for sermorelin alongside recovery or exercise returns eight records. Two are recent review articles surveying peptide therapies broadly across sports medicine and orthopedics [2][3]; the rest are unrelated detection-chemistry papers. None is a primary trial measuring sermorelin’s effect on recovery in humans. This is not a claim that failed a test. It is a claim nobody has run the test for.

Why “raises growth hormone” isn’t on this list

One sermorelin claim is missing from the six above on purpose: that it raises growth hormone itself. That part is well established — nightly dosing produced a measurable GH pulse within ten minutes, sustained across the same five-month trial, with IGF-1 rising within two weeks [1]. It is the one link in the chain that repeated testing has confirmed. But raising a hormone is not the same thing as delivering a benefit a person would notice, and every claim ranked above is about the second thing, not the first. See the dose that trial actually used, which sits above what most sellers market. A seller’s page rarely separates the two claims; the mechanism is real, and it is doing a lot of marketing work it was not designed to carry alone.

What the ranking doesn’t fix

Every positive result above shares three limits worth holding onto together. Each comes from the same single 1997 trial. Each was measured at 10 micrograms per kilogram nightly — well below the 200 to 300 micrograms a night that commercial protocols commonly advertise, a dose range no published trial has tested. And every positive result that split by sex split the same way: something for men, nothing for women on the same measure. A seller’s page rarely mentions any of the three. For what a sermorelin protocol can do to a person besides these six benefit claims, see the separate side-effect evidence.

None of this makes the positive findings fake. Lean mass, skin thickness, well-being and libido moved in a real, randomized, placebo-controlled study. It means the honest version of each claim is smaller and more conditional than the marketing version. For two of the six most-repeated claims, sleep and recovery, the honest version is that the evidence either failed the test or was never given one.

How the six claims compare, side by side

ClaimWhat was actually foundSexTrials
LibidoSignificant improvement, P < 0.01Men only1
Skin thicknessSignificant increase, P < 0.05Both1
Body composition (lean mass)Significant increase, P < 0.05Men only1
Anti-aging / well-beingSignificant improvement, P < 0.05Men only1
SleepNo significant changeNeither1 (tested, negative)
RecoveryNo trial exists0

Read across that table and the pattern is consistent: one trial, one dose, mostly one sex. A claim sitting near the top of this ranking is still a single, decades-old data point — not a settled result. For a broader look at how to weigh a single small trial against a marketing claim, see how to read a peptide study.

Frequently asked

Is any sermorelin claim backed by more than one trial?
No. Every adult efficacy finding on this list — libido, skin thickness, lean body mass, general well-being — comes from the same single 1997 trial in nineteen adults. None has been independently replicated.
Which sermorelin claim has the least evidence behind it?
Recovery. A PubMed search for sermorelin combined with recovery or exercise returns eight records, none of them a primary human trial testing sermorelin for recovery. It is the only one of the six claims with zero direct trial evidence, positive or negative.
Did any claim actually fail when it was tested?
Yes — sleep. It was measured directly in the 1997 trial and reported as unaffected in both sexes, and a broader search for sermorelin and sleep turns up no positive human sleep-outcome trial among eight records.
Do these findings apply equally to women?
No. Every positive adult result — libido, lean body mass, general well-being — was significant in men only. Skin thickness is the exception; it improved in both sexes. Women showed no change on any other body-composition or quality-of-life measure the 1997 trial tested.

Sources

  1. [1] Khorram O, Laughlin GA, Yen SS. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology and Metabolism. PMID 9141536
  2. [2] Mendias CL, Awan TM. (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Medicine (Auckland, N.Z.). PMID 41966639
  3. [3] Rahman OF, Lee SJ, Seeds WA. (2026). Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews. PMID 41490200

Where to get it

Best sermorelin injections

Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured.

Compare providers →

More in Evidence